Adult form of Langerhans cell histiocytosis with pulmonary and hepatic Involvement mimicking malignancy in a patient with chronic hepatitis C infection by Moullet, Barbara et al.
R a d i o l o g y  C a s e  R e p o r t s  1 6  ( 2 0 2 1 )  3 2 7 – 3 3 3  
Available online at www.sciencedirect.com 
journal homepage: www.elsevier.com/locate/radcr 
Case Report 
Adult form of Langerhans cell histiocytosis with 
pulmonary and hepatic involvement mimicking 
malignancy in a patient with chronic hepatitis C 
infection 
Barbara Moullet, MD a , Mirjam Kolev, MD b , Lukas Ebner, MD a , Rupert Langer, MD c , 
Christoph Gräni, MD, PhD d , Verena Obmann, MD a , Martin Maurer, MD a , 
Nasser Semmo, MD, PhD b , Andreas Christe, MD a , Adrian Thomas Huber, MD, PhD a , ∗
a Department of Diagnostic, Interventional and Pediatric Radiology, Inselspital University Hospital, University of 
Bern, Freiburgstrasse 10, Inselspital, 3010, Bern, Switzerland 
b Hepatology, Department of Visceral Surgery and Medicine, Inselspital University Hospital, University of Bern, Bern, 
Switzerland 
c Department of Pathology, Inselspital University Hospital, University of Bern, Bern, Switzerland 
d Department of Cardiology, Inselspital University Hospital, University of Bern, Bern, Switzerland 
a r t i c l e i n f o 
Article history: 
Received 12 August 2020 
Revised 9 November 2020 
Accepted 11 November 2020 
Keywords: 
Langerhans cell histiocytosis 
Hepatitis C 
Liver 
Liver cirrhosis 
Hepatocellular 
Carcinoma 
a b s t r a c t 
Langerhans cell histiocytosis (LCH) is a myeloid neoplasm with inflammatory properties. 
There are few published reports of adult LCH with liver involvement, which is still poorly un- 
derstood, but shows high morbidity and mortality. We report a case of a 37-year-old woman 
suffering from hepatitis C showing a LCH affecting the lung as well as the liver. Consistent 
with histology, we found an early stage of a proliferative/granulomatous phase of hepato- 
biliary LCH, whereas pulmonary findings showed a nodular stage of adult pulmonary LCH. 
Although hepatocellular carcinoma is a common malignancy in patients suffering from hep- 
atitis C, it is crucial to keep in mind differential diagnosis for newly appearing liver lesions. 
© 2020 Published by Elsevier Inc. on behalf of University of Washington. 
This is an open access article under the CC BY-NC-ND license 
( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) 
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Introduction 
Langerhans cell histiocytosis (LCH) is a myeloid neoplasm
with inflammatory properties [1] . It most often affects the∗ Corresponding author. 
E-mail address: Adrian.huber@insel.ch (A.T. Huber). 
https://doi.org/10.1016/j.radcr.2020.11.022 
1930-0433/© 2020 Published by Elsevier Inc. on behalf of University of W
BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ )bones in children, with a peak between the age of 1 and 4
years old [2 ,3] . LCH can affect single (unifocal) or multiple
organs of the human body (systemic) [4 ,5] . Mortality is in-
creased in patients suffering from multiorgan involvement,
especially when the reticuloendothelial system is involvedashington. This is an open access article under the CC 
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Fig. 1 – Contrast-enhanced ultrasound (CEUS) of one of the hepatic lesions (white arrow). ( A) Gray scale image with 
hypoechogenic lesion in liver segment III; ( B) late arterial phase showing contrast enhancement of the lesion with venous wash-out 
in ( C). Please note contrast enhancement of the aorta as a reference to recognize the arterial and the venous phase (asterisk). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(spleen, liver, bone marrow) [6 ,7] . The presence of a BRAF-
mutation is an important prognostic factor associated with
systemic LCH and poor survival [8 ,9] . 
The adult form of LCH is rare, the exact incidence is un-
known. Some authors estimate an incidence of 1-2 cases of
LCH per million adults per year, while the pulmonary form oc-
curs most frequently, being associated with smoking [10–13] .
In a series of 502 open lung biopsies for chronic diffuse infil-
trative lung disease in 1980, diagnosis of pulmonary LCH was
made in 17 patients (3.4%) [14] . There are few published re-
ports of adult LCH with liver involvement, which is still poorly
understood, but may show high morbidity and mortality [15] .
We report a case of a 37-year-old woman suffering from LCH
affecting the lung as well as the liver. 
Case presentation 
A 37-year-old woman known for a low replicative chronic hep-
atitis C (HCV) infection was seen for a follow-up in our out-
patient clinic. HCV infection was due to an intravenous drug
abuse in the past. She was asymptomatic and in good gen-
eral condition. Besides being an active smoker (15 py), she had
a history of intravenous drug abuse but stopped many years
ago. She was under substitution therapy with buprenorphine
and took the antidepressant bupropion as well as vitamin D3.
She was vaccinated for hepatitis A and B and HIV negative.
Up until this date, the patient had not been treated for HCV
due to normal liver tests, low and declining replication sta-
tus (max copies measured 3295 IU/mL 2015, 520 IU/mL 2017,
and 38 IU/mL 2019) and no signs of fibrosis or cirrhosis in
fibroscan and ultrasound. Routine liver enzyme tests, blood
count, and inflammatory markers were normal. In search for
signs of fibrosis and focal liver lesions, abdominal sonography
was performed. It revealed a liver with a normal parenchy-
mal aspect and no signs of portal hypertension. Surprisingly,
one small hypoechoic lesion with 10 × 13 mm in size was
seen in segment III. For better characterization of the lesion,
contrast-enhanced ultrasound was performed, showing an ar-terial contrast enhancement and a venous was-hout ( Fig. 1 A-
C), typical features of a neoplastic lesion. 
Subsequently, an MRI of the liver was performed, which
confirmed the sonographic findings. A noncirrhotic liver
parenchyma with several small T1w hypointense, T2w hyper-
intense lesions ( ≤15 mm) in both liver lobes with predomi-
nance in the right lobe was seen. No macroscopic or micro-
scopic fat was present on the fat-saturated images and on
the T1 Dixon in and out of phase acquisitions. After intra-
venous administration of gadoxetic acid (Primovist), the le-
sions showed a rim-like enhancement in the arterial phase
and central hypointensities in the venous and hepatobiliary
phase, as well as diffusion restriction ( Fig. 2 A-F). T1 reduction
rate ( T1) in the hepatobiliary phase based on T1-mapping
was 84%, consistent with normal hepatocellular liver function
(T1 relaxation time pre contrast = 916 ms, T1 relaxation time
in the hepatobiliary phase = 149 ms, considering T1 ≥60% as
a normal liver function) [16] ( Fig. 3 A and B). Intra- and extra-
hepatic bile tracts were normal. 
Characteristics of the hepatic lesions were similar to those
of a multifocal hepatocellular carcinoma (HCC) with diffu-
sion restriction, arterial phase enhancement, and central hy-
pointensity in the venous and hepatobiliary phase. However,
our patient was young and despite chronic hepatitis C, there
were no signs of liver fibrosis or cirrhosis. Therefore, further
investigations were necessary. The tumor markers alphafeto
protein (HCC) and chromogranin A II (neuroendocrine tumor)
were negative. Gastroscopy and colonoscopy were normal. To
rule out metastatic disease, a thoracoabdominal CT was per-
formed, showing no visible tumor of the pancreas, kidneys
or gastrointestinal tract, and no identifiable lymphadenopa-
thy. However, multiple pulmonary nodules ( ≤8 mm) with up-
per lobe predominance and sparing of the subpleural space
were found. Many of those nodules exhibited cystic changes,
raising the suspicion of pulmonary LCH ( Fig. 4 A and B). The
surrounding pulmonary parenchyma showed no alterations
and there was no thoracic lymphadenopathy. The differential
diagnosis of the radiological findings included septic emboli
and fungal affection in a patient with a history of intravenous
drug abuse. However, as our patient had not been an active
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Fig. 2 – MRI of the liver with one liver lesion in segment VI. The lesion is slightly hyperintense on T2-weighted images (A) . 
On T1-weighted images, the lesion is hypointense before contrast administration (B) and shows an avid rim-like 
enhancement in the arterial phase (C) with central hypointensity in the venous phase (D) and no gadoxetic acid uptake in 
the hepatobiliary phase (E) . Diffusion-weighted imaging shows diffusion restriction (F) . 
Fig. 3 – shMOLLI T1 – mapping images with the lesion. ( A) Precontrast ( B) postcontrast in the hepatobiliary phase, 20 
minutes after intravenous administration of gadoxetic acid. T1 relaxation time of the liver pre contrast was 916 ms and 149 
ms in the hepatobiliary phase, with a calculated T1 reduction rate ( T1) of 84%, consistent with a normal hepatocellular 
function of the liver. Please note a hepatic lesion in liver segment V with longer precontrast T1 relaxation time as compared 
to the adjacent liver parenchyma. The lesion shows a reduced T1 shortening after gadoxetic acid administration, consistent 
with a nonhepatocellular lesion (white arrow). 
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Fig. 4 – CT scan showing multiple pulmonary nodules with upper lobe predominance. On the axial (A) and coronal images 
(B) multiple cystic changes are seen (white arrows). Please note paraseptal emphysema (black arrow in B) in this patient 
with a history of smoking, but no signs of pulmonary fibrosis. Maximum intensity projection (MIP) reconstructions illustrate 
the upper lobe predominance of the pulmonary nodules (C) . 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
intravenous drug abuser for many years, this was unlikely in
the clinical context. 
After discussion in our multidisciplinary board, we de-
cided to perform a liver biopsy to exclude HCC and metastasis
and to confirm our suspicion of a rare case of LCH with pul-
monary and hepatic involvement. On histology, circumscript
infiltrates of atypical histiocytic cells were found ( Fig. 5 A), in-
termingled with eosinophilic granulocytes, and lymphocytes
( Fig. 5 C). Immunohistochemistry showed positivity for CD1a in
the histiocytic cells ( Fig. 5 B to D). No BRAF (V600E) mutation
was found in immunohistochemistry. Taken together, these
findings established the diagnosis of LCH in the liver. As pul-
monary radiological findings were compatible with LCH, the
diagnosis of LCH with pulmonary and hepatic involvement
was made. Our examinations showed no further organ mani-
festations (skin, lymph nodes or bones). After another discus-sion in our multi-disciplinary board, a watch and wait strat-
egy was chosen for this asymptomatic patient presenting in a
non-fibrotic stage of LCH. 
The patient was encouraged to discontinue smoking, since
the effect of nicotine abuse stimulating recurrence or pro-
gression of pulmonary LCH is well described [17] . Whether
chronic hepatitis C was an additional factor for LCH develop-
ment in the liver is unclear (see discussion). As the association
of chronic hepatitis C in other hematological tumors is known
(foremost non-Hodgkin-lymphoma [18] ) and the oncogenic
Ras-ERK pathway signaling in LCH pathogenesis is described
in many cases [1 ,19] , also having a link to the mechanism of
hepatitis C [20] , we favored to treat the patient for hepatitis C.
In the follow-up consultation 4 months later, the patient
was still asymptomatic, she quit smoking, liver enzymes were
normal and the liver lesion in segment III was smaller in size
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Fig. 5 – Histology showing circumscript infiltrates of atypical histiocytic cells (A to C) . Immunohistochemistry for CD1a 
demonstrate (brown-stained areas) positive staining in Langerhans cells (B to D). (A to B) are shown with a 2 ×
magnification, (C to D) with a 20 × magnification. Scale bars (500 μm and 50 μm) are included on the bottom left of the 
images. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(10 mm in diameter compared to 13 mm previously). Interest-
ingly enough, she had spontaneously and persistently cleared
the hepatitis C virus. 
Discussion 
We present a case with a challenging diagnostic process of an
adult form of LCH with pulmonary and hepatic involvement.
This case shows that arterial enhancing nodules with cen-
tral hypointensity in the venous phase in the liver are not al-
ways consistent with HCC. Especially in cases of a noncirrhotic
liver, differential diagnosis such as metastatic, infectious, and
systemic diseases should be considered, while other imaging
findings can lead to the correct diagnosis. Here, partially cav-
itary nodules ( ≤8 mm) of the lungs with upper lobe predomi-
nance and sparing of the subpleural space raised suspicion of
an adult form of LCH with predominant pulmonary, but also
hepatic involvement [21] . 
Lung 
Pulmonary LCH shows variable appearance and is associated
with nicotine abuse [17] . Significantly enlarged mediastinal
lymph nodes and pleural effusion are rarely observed in pa-
tients suffering from LCH [3 ,22] . Early during disease, LCH
presents in a nodular stage, histologically characterized by in-
terstitial Langerhans-cellular infiltrates centered on the walls
of bronchioles. On CT, the typical findings are small, some-
times with cystic changes (1-10 mm) with peribronchovas-
cular distribution, sparing the costophrenic angle, and upperlobe predominance [23–25] . In the early phase, no significant
fibrotic alterations of the surrounding parenchyma are seen.
In the late, fibrotic course of LCH, formation of pulmonary
cysts occurs. Pathophysiologically it is assumed that the for-
mation of thin walled cysts is due to a check-valve bronchial
obstruction by the nodules, causing dilatation of distal air-
ways, and the occurrence of interstitial fibrosis with archi-
tectural distortion. Those irregular shaped cysts may have di-
ameters up to 2-3 cm and may coalesce to bronchiectasis or
emphysema [13] . Histologically, various appearances can oc-
cur, such as focal scarring, confluent fibrosis or diffuse hon-
eycombing, which may be difficult to distinguish from hon-
eycombing in patients having other interstitial diseases. In
the late fibrotic course of disease, spontaneous pneumotho-
races can occur [3] . In a series of 102 adults with histologically
proven adult pulmonary LCH, Vassallo et al found an extrapul-
monary involvement in 17 patients (involvement of the pitu-
itary gland in 8 patients, bone in 4 patients, skin in 4 patients
and lymph nodes or liver in 4 patients) with an estimated me-
dian survival of 12.5 years [26] . 
Liver 
Hepatic involvement of LCH is rare in adults and is usually
seen along with pulmonary involvement in the adult form
of LCH [27] . Generally, there are 4 histological stages of hep-
atic LCH with corresponding imaging features: proliferative,
granulomatous, xanthomatous, and fibrous phase, which
may lead to liver failure [3] . During the proliferative and
granulomatous phase, histology shows periportal infiltration
of Langerhans cells and other inflammatory cells, causing
periportal inflammation with edema. Ultrasound shows
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hypoechoic band like or nodular areas with periportal distri-
bution. Similarly, hypodense lesions are visible on CT, while
T1-weighted hypointense and T2-weighted hyperintense
lesions are visible on MRI [3] . The xanthomatous stage of dis-
ease is characterized by histiocytes ingesting fat containing
cell membrane debris, leading to a foamy consistency of the
histiocytes. Accordingly, imaging shows linear periportal fatty
lesions. On Ultrasound they appear hyperechoic, while on CT
scan they are hypodense, and on native T1w-MRI without fat
suppression the appearance is hyperintense [28 ,29 ,3] . In the
fibrous phase, liver parenchyma shows dysmorphic and nodu-
lar alterations, due to extensive periductal fibrosis, secondary
causing portal hypertension [28 ,30 ,31] . In imaging, primary or
secondary sclerosing cholangitis leads to biliary irregularities
with segmental narrowing and dilatation, resulting in a
beaded appearance of the bile ducts at conventional cholan-
giography, ERCP, or MR cholangiopancreatography [3] . Liver
fibrosis may be characterized with transient elastography
(Fibroscan) or MR-elastography. 
Hepatitis C and LCH 
Hepatitis C (HCV) is a risk factor for developing hepatocellular
carcinoma, mostly in the setting of advanced fibrosis/cirrhosis
of the liver. Recently, more data were published on the possible
molecular mechanisms. One of those is the activation of the
pro oncogenic MEK/ERK pathway [20] . 
This pathway seems to be crucial in the development of
LCH as well [19] , suggesting hepatitis C infection being a risk
factor for LHC in the liver. However, due to the rareness of the
disease, there is no association described besides some scarce
case reports found in the literature [32 ,33] . 
After the novel direct-acting antiviral agent (DAA) was in-
troduced in clinical practice, concern was expressed that this
therapy may increase the risk of de novo HCC [34] . This was
based on descriptive studies observing a higher than histori-
cally expected proportion of patients who developed HCC af-
ter antiviral treatment. The biological mechanism that was
proposed was that rapid viral clearance with DAAs could lead
to reduced cancer immune surveillance and antitumor activ-
ity. Studies that are more recent provide evidence that DAA-
induced eradication of hepatitis C reduces HCC risk [35] . This
discussion was a factor making us more alert as to whether
the treatment of the hepatitis C in our patient would be of
benefit or could even provoke harm due to the change of local
immunity. 
Hepatitis C virus is not only a hepatotropic, but also a lym-
photropic virus and HCV-associated non-Hodgkin lymphomas
are a well-described entity. Hematologic remission in HCV-
associated indolent lymphoma can be achieved by treating
HCV [18] . Therefore, we decided to treat the patient with DAA
for the hepatitis C. However, interestingly the patient had a
negative HCV RNA in 2 subsequent follow-up visits and there-
fore cleared the HCV spontaneously. 
Conclusion 
We present a rare case of adult LCH with synchronous hepatic
and pulmonary involvement in a nonfibrotic stage of disease.Consistent with histology, we found an early stage of a pro-
liferative/granulomatous phase of hepatobiliary LCH without
any fat containing liver lesions, normal hepatocellular func-
tion, and no significant fibrotic liver remodeling. This is con-
sistent with the pulmonary findings, showing a nodular stage
of adult pulmonary LCH without any signs of architectural dis-
tortion or pulmonary fibrosis. 
Statement 
Written, informed consent for publication of her case was ob-
tained from the patient. 
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